The efficacy and agreeability of a supportive
drug therapy at doses of 300 mg of
proquazone (
Biarison) administered thrice daily was tested in an open study of 4 weeks' duration in 10 male patients suffering of clinically verified
ankylosing spondylitis. The minimum duration of suffering was 15 years, the maximum 50 years. The major goal of
therapy during clinical treatment was individually oriented
physical therapy suited to the enhancement of residual mobility, removal of postural abnormalities and abnormalities of weight-loading as well as the maintenance of functionality for afflicted skeletal regions. In the course of this additional
therapy with
proquazone the functional index and activity index both displayed significant improvement (2 p less than 0.01), as compared with the control subjects. Improvement was attained as soon
as 2 weeks following begin of
therapy. In the course of treatment the following parameters also displayed significant improvement (2 p less than 0.05): morning stiffness,
fatigue, patient's self-evaluation, Westergren one-hour-value, physician's over-all assessment, night
pain, articular
pain, thoracic and lumbar
pain. There were only insignificant changes in other, regularly tested laboratory values during this
drug therapy. No side effects or disagreeability signs of
proquazone were noted.
Proquazone can be recommended for the symptomatic additional treatment of patients suffering from
ankylosing spondylitis.